• Molecular NameBudipine
  • SynonymNA
  • Weight293.454
  • Drugbank_IDN/A
  • ACS_NO57982-78-2
  • Show 2D model
  • LogP (experiment)5.1
  • LogP (predicted, AB/LogP v2.0)4.81
  • pka10.55
  • LogD (pH=7, predicted)2.06
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.9
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.1
  • No.of HBond Donors0
  • No.of HBond Acceptors1
  • No.of Rotatable Bonds3
  • TPSA3.24
  • StatusN/A
  • AdministrationN/A
  • PharmacologyA dopaminergic agent. It is believed to be a NMDA receptor antagonist, and to promote the synthesis of dopamine.
  • Absorption_valueN/A
  • Absorption (description)It is well absorbed after oral administration (about 80%).
  • Caco_2N/A
  • Bioavailability47.0
  • Protein binding96.0
  • Volume of distribution (VD)2.7 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt mainly metabolises to mono-p-hydroxybudipine which is significantly less active than budipine.
  • Half life30 h
  • ExcretionAbout 80% of a dose is excreted via the kidneys, partly as unchanged budipine and to a greater extent as the hydroxymetabolite.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityCan be poisonous intravenously.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A